APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hereditary Angioedema Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hereditary Angioedema Drug Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchHereditary Angioedema Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hereditary Angioedema Drug Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Hereditary Angioedema Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hereditary Angioedema Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hereditary Angioedema Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Hereditary Angioedema Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hereditary Angioedema Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hereditary Angioedema Drug market include Takeda, Pharming Group NV, Ionis Pharmaceuticals, Inc., IBio Inc., CSL Limited and BioCryst Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hereditary Angioedema Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hereditary Angioedema Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hereditary Angioedema Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hereditary Angioedema Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hereditary Angioedema Drug Segment by Company

Takeda

Pharming Group NV

Ionis Pharmaceuticals, Inc.

IBio Inc.

CSL Limited

BioCryst Pharmaceuticals, Inc.

Hereditary Angioedema Drug Segment by Type

C1 Esterase Inhibitor

Kallikrein Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Hereditary Angioedema Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hereditary Angioedema Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hereditary Angioedema Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hereditary Angioedema Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hereditary Angioedema Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Hereditary Angioedema Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hereditary Angioedema Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hereditary Angioedema Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hereditary Angioedema Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hereditary Angioedema Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hereditary Angioedema Drug industry.

Chapter 3: Detailed analysis of Hereditary Angioedema Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hereditary Angioedema Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hereditary Angioedema Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hereditary Angioedema Drug Industry Trends Table 2. Hereditary Angioedema Drug Industry Drivers Table 3. Hereditary Angioedema Drug Industry Opportunities and Challenges Table 4. Hereditary Angioedema Drug Industry Restraints Table 5. Global Hereditary Angioedema Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hereditary Angioedema Drug Revenue Share by Company (2021-2026) Table 7. Global Hereditary Angioedema Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Hereditary Angioedema Drug Sales Volume Share by Company (2021-2026) Table 9. Global Hereditary Angioedema Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Hereditary Angioedema Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hereditary Angioedema Drug Key Company Manufacturing Base & Headquarters Table 12. Global Hereditary Angioedema Drug Company, Product Type & Application Table 13. Global Hereditary Angioedema Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hereditary Angioedema Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of C1 Esterase Inhibitor Table 18. Significant Companies of Kallikrein Inhibitor Table 19. Significant Companies of Selective Bradykinin B2 Receptor Antagonist Table 20. Global Hereditary Angioedema Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Hereditary Angioedema Drug Sales Volume by Type (2021-2026) & (W Units) Table 22. Global Hereditary Angioedema Drug Sales Volume by Type (2027-2032) & (W Units) Table 23. Global Hereditary Angioedema Drug Sales Volume Share by Type (2021-2026) Table 24. Global Hereditary Angioedema Drug Sales Volume Share by Type (2027-2032) Table 25. Global Hereditary Angioedema Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Hereditary Angioedema Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Hereditary Angioedema Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Hereditary Angioedema Drug Sales Value Share by Type (2021-2026) Table 29. Global Hereditary Angioedema Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Pharmacies Table 31. Significant Companies of Online Pharmacies Table 32. Significant Companies of Retail Pharmacies Table 33. Global Hereditary Angioedema Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Hereditary Angioedema Drug Sales Volume by Application (2021-2026) & (W Units) Table 35. Global Hereditary Angioedema Drug Sales Volume by Application (2027-2032) & (W Units) Table 36. Global Hereditary Angioedema Drug Sales Volume Share by Application (2021-2026) Table 37. Global Hereditary Angioedema Drug Sales Volume Share by Application (2027-2032) Table 38. Global Hereditary Angioedema Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Hereditary Angioedema Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Hereditary Angioedema Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Hereditary Angioedema Drug Sales Value Share by Application (2021-2026) Table 42. Global Hereditary Angioedema Drug Sales Value Share by Application (2027-2032) Table 43. Global Hereditary Angioedema Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Hereditary Angioedema Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Hereditary Angioedema Drug Sales Market Share by Region (2021-2026) Table 46. Global Hereditary Angioedema Drug Sales by Region (2027-2032) & (W Units) Table 47. Global Hereditary Angioedema Drug Sales Market Share by Region (2027-2032) Table 48. Global Hereditary Angioedema Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Hereditary Angioedema Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Hereditary Angioedema Drug Sales Value Share by Region (2021-2026) Table 51. Global Hereditary Angioedema Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Hereditary Angioedema Drug Sales Value Share by Region (2027-2032) Table 53. Global Hereditary Angioedema Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Hereditary Angioedema Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Hereditary Angioedema Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Global Hereditary Angioedema Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 58. Global Hereditary Angioedema Drug Sales Market Share by Country (2021-2026) Table 59. Global Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 60. Global Hereditary Angioedema Drug Sales Market Share by Country (2027-2032) Table 61. Global Hereditary Angioedema Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Hereditary Angioedema Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Hereditary Angioedema Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Hereditary Angioedema Drug Sales Value Market Share by Country (2027-2032) Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Takeda Hereditary Angioedema Drug Product Portfolio Table 69. Takeda Recent Development Table 70. Pharming Group NV Company Information Table 71. Pharming Group NV Business Overview Table 72. Pharming Group NV Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Pharming Group NV Hereditary Angioedema Drug Product Portfolio Table 74. Pharming Group NV Recent Development Table 75. Ionis Pharmaceuticals, Inc. Company Information Table 76. Ionis Pharmaceuticals, Inc. Business Overview Table 77. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 79. Ionis Pharmaceuticals, Inc. Recent Development Table 80. IBio Inc. Company Information Table 81. IBio Inc. Business Overview Table 82. IBio Inc. Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. IBio Inc. Hereditary Angioedema Drug Product Portfolio Table 84. IBio Inc. Recent Development Table 85. CSL Limited Company Information Table 86. CSL Limited Business Overview Table 87. CSL Limited Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. CSL Limited Hereditary Angioedema Drug Product Portfolio Table 89. CSL Limited Recent Development Table 90. BioCryst Pharmaceuticals, Inc. Company Information Table 91. BioCryst Pharmaceuticals, Inc. Business Overview Table 92. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 94. BioCryst Pharmaceuticals, Inc. Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Hereditary Angioedema Drug Distributors List Table 98. Hereditary Angioedema Drug Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Hereditary Angioedema Drug Product Image Figure 2. Global Hereditary Angioedema Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hereditary Angioedema Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hereditary Angioedema Drug Sales (2021-2032) & (W Units) Figure 5. Global Hereditary Angioedema Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Hereditary Angioedema Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. C1 Esterase Inhibitor Image Figure 10. Kallikrein Inhibitor Image Figure 11. Selective Bradykinin B2 Receptor Antagonist Image Figure 12. Global Hereditary Angioedema Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Hereditary Angioedema Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Hereditary Angioedema Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Hereditary Angioedema Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Hereditary Angioedema Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Hereditary Angioedema Drug Sales Value Share by Type (2021-2032) Figure 18. Hospital Pharmacies Image Figure 19. Online Pharmacies Image Figure 20. Retail Pharmacies Image Figure 21. Global Hereditary Angioedema Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Hereditary Angioedema Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Hereditary Angioedema Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Hereditary Angioedema Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Hereditary Angioedema Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Hereditary Angioedema Drug Sales Value Share by Application (2021-2032) Figure 27. Global Hereditary Angioedema Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 28. Global Hereditary Angioedema Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Hereditary Angioedema Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Hereditary Angioedema Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Hereditary Angioedema Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Hereditary Angioedema Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Hereditary Angioedema Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Hereditary Angioedema Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Hereditary Angioedema Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Hereditary Angioedema Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Hereditary Angioedema Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Hereditary Angioedema Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Hereditary Angioedema Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Hereditary Angioedema Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Hereditary Angioedema Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Hereditary Angioedema Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda
  • Pharming Group NV
  • Ionis Pharmaceuticals, Inc.
  • IBio Inc.
  • CSL Limited
  • BioCryst Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hereditary Angioedema Drug Sales Value (2021-2032)
  4. 1.2.2 Global Hereditary Angioedema Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Hereditary Angioedema Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hereditary Angioedema Drug Market Dynamics
  1. 2.1 Hereditary Angioedema Drug Industry Trends
  2. 2.2 Hereditary Angioedema Drug Industry Drivers
  3. 2.3 Hereditary Angioedema Drug Industry Opportunities and Challenges
  4. 2.4 Hereditary Angioedema Drug Industry Restraints
3 Hereditary Angioedema Drug Market by Company
  1. 3.1 Global Hereditary Angioedema Drug Company Revenue Ranking in 2025
  2. 3.2 Global Hereditary Angioedema Drug Revenue by Company (2021-2026)
  3. 3.3 Global Hereditary Angioedema Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Hereditary Angioedema Drug Average Price by Company (2021-2026)
  5. 3.5 Global Hereditary Angioedema Drug Company Ranking (2024-2026)
  6. 3.6 Global Hereditary Angioedema Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Hereditary Angioedema Drug Company Product Type and Application
  8. 3.8 Global Hereditary Angioedema Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hereditary Angioedema Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hereditary Angioedema Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hereditary Angioedema Drug Market by Type
  1. 4.1 Hereditary Angioedema Drug Type Introduction
  2. 4.1.1 C1 Esterase Inhibitor
  3. 4.1.2 Kallikrein Inhibitor
  4. 4.1.3 Selective Bradykinin B2 Receptor Antagonist
  5. 4.2 Global Hereditary Angioedema Drug Sales Volume by Type
  6. 4.2.1 Global Hereditary Angioedema Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Hereditary Angioedema Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Hereditary Angioedema Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Hereditary Angioedema Drug Sales Value by Type
  10. 4.3.1 Global Hereditary Angioedema Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Hereditary Angioedema Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Hereditary Angioedema Drug Sales Value Share by Type (2021-2032)
5 Hereditary Angioedema Drug Market by Application
  1. 5.1 Hereditary Angioedema Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Hereditary Angioedema Drug Sales Volume by Application
  6. 5.2.1 Global Hereditary Angioedema Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hereditary Angioedema Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hereditary Angioedema Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hereditary Angioedema Drug Sales Value by Application
  10. 5.3.1 Global Hereditary Angioedema Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hereditary Angioedema Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hereditary Angioedema Drug Sales Value Share by Application (2021-2032)
6 Hereditary Angioedema Drug Regional Sales and Value Analysis
  1. 6.1 Global Hereditary Angioedema Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hereditary Angioedema Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hereditary Angioedema Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Hereditary Angioedema Drug Sales by Region (2027-2032)
  5. 6.3 Global Hereditary Angioedema Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hereditary Angioedema Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hereditary Angioedema Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hereditary Angioedema Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Hereditary Angioedema Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hereditary Angioedema Drug Sales Value (2021-2032)
  12. 6.6.2 North America Hereditary Angioedema Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hereditary Angioedema Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Hereditary Angioedema Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hereditary Angioedema Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hereditary Angioedema Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hereditary Angioedema Drug Sales Value (2021-2032)
  21. 6.9.2 South America Hereditary Angioedema Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hereditary Angioedema Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hereditary Angioedema Drug Sales Value Share by Country, 2025 VS 2032
7 Hereditary Angioedema Drug Country-level Sales and Value Analysis
  1. 7.1 Global Hereditary Angioedema Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hereditary Angioedema Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hereditary Angioedema Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Hereditary Angioedema Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Hereditary Angioedema Drug Sales by Country (2027-2032)
  6. 7.4 Global Hereditary Angioedema Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hereditary Angioedema Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hereditary Angioedema Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hereditary Angioedema Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hereditary Angioedema Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hereditary Angioedema Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Hereditary Angioedema Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Hereditary Angioedema Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Pharming Group NV
  8. 8.2.1 Pharming Group NV Company Information
  9. 8.2.2 Pharming Group NV Business Overview
  10. 8.2.3 Pharming Group NV Hereditary Angioedema Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pharming Group NV Hereditary Angioedema Drug Product Portfolio
  12. 8.2.5 Pharming Group NV Recent Developments
  13. 8.3 Ionis Pharmaceuticals, Inc.
  14. 8.3.1 Ionis Pharmaceuticals, Inc. Company Information
  15. 8.3.2 Ionis Pharmaceuticals, Inc. Business Overview
  16. 8.3.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  18. 8.3.5 Ionis Pharmaceuticals, Inc. Recent Developments
  19. 8.4 IBio Inc.
  20. 8.4.1 IBio Inc. Company Information
  21. 8.4.2 IBio Inc. Business Overview
  22. 8.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 IBio Inc. Hereditary Angioedema Drug Product Portfolio
  24. 8.4.5 IBio Inc. Recent Developments
  25. 8.5 CSL Limited
  26. 8.5.1 CSL Limited Company Information
  27. 8.5.2 CSL Limited Business Overview
  28. 8.5.3 CSL Limited Hereditary Angioedema Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CSL Limited Hereditary Angioedema Drug Product Portfolio
  30. 8.5.5 CSL Limited Recent Developments
  31. 8.6 BioCryst Pharmaceuticals, Inc.
  32. 8.6.1 BioCryst Pharmaceuticals, Inc. Company Information
  33. 8.6.2 BioCryst Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  36. 8.6.5 BioCryst Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hereditary Angioedema Drug Value Chain Analysis
  2. 9.1.1 Hereditary Angioedema Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hereditary Angioedema Drug Sales Mode & Process
  6. 9.2 Hereditary Angioedema Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hereditary Angioedema Drug Distributors
  9. 9.2.3 Hereditary Angioedema Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst